GUARNOTTA, Valentina
 Distribuzione geografica
Continente #
NA - Nord America 5.644
EU - Europa 2.104
AS - Asia 925
AF - Africa 18
SA - Sud America 16
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.714
Nazione #
US - Stati Uniti d'America 5.631
IT - Italia 986
CN - Cina 516
SG - Singapore 285
FI - Finlandia 234
DE - Germania 210
IE - Irlanda 149
UA - Ucraina 128
GB - Regno Unito 114
SE - Svezia 57
FR - Francia 56
RU - Federazione Russa 54
BE - Belgio 30
TR - Turchia 30
IN - India 29
KR - Corea 28
RO - Romania 23
NL - Olanda 20
CI - Costa d'Avorio 15
HK - Hong Kong 9
MX - Messico 9
PL - Polonia 9
GR - Grecia 7
PE - Perù 7
BR - Brasile 6
CH - Svizzera 5
DK - Danimarca 5
ES - Italia 5
TW - Taiwan 5
UZ - Uzbekistan 5
VN - Vietnam 4
AT - Austria 3
AU - Australia 3
CA - Canada 3
CZ - Repubblica Ceca 3
JP - Giappone 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CO - Colombia 2
IL - Israele 2
IR - Iran 2
LB - Libano 2
MK - Macedonia 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
ZA - Sudafrica 1
Totale 8.714
Città #
Fairfield 886
Ashburn 516
Houston 478
Woodbridge 446
Chandler 393
Wilmington 376
Seattle 373
Cambridge 278
Ann Arbor 249
Singapore 218
Medford 159
Palermo 150
Dublin 146
Princeton 99
Altamura 96
Des Moines 94
Nanjing 86
Jacksonville 68
Lawrence 63
San Diego 55
Beijing 49
Ludwigshafen am Rhein 49
Santa Clara 48
Boardman 45
Dearborn 43
New York 42
Nanchang 35
Jinan 34
London 34
Rome 33
Milan 31
Brussels 29
Changsha 29
Shenyang 29
Hebei 28
Izmir 27
Tulsa 27
Ningbo 25
Jiaxing 23
Phoenix 22
Redwood City 22
Tianjin 22
Falls Church 18
Zhengzhou 16
Abidjan 15
Bucheon-si 14
Saint Petersburg 14
Guangzhou 13
Hangzhou 13
San Paolo di Civitate 13
Haikou 12
Kumar 12
Frankfurt 11
Los Angeles 11
Norwalk 11
Pune 11
Seongnam 11
Taizhou 11
Atlanta 10
Columbus 10
Lappeenranta 10
Chicago 9
Napoli 9
Taiyuan 9
Auburn Hills 8
Central 8
Kunming 8
Amsterdam 7
Bari 7
Bremen 7
Dallas 7
Den Haag 7
Lima 7
Orange 7
Venice 7
Helsinki 6
Kilburn 6
Verona 6
Washington 6
West Jordan 6
Atripalda 5
Cagliari 5
Munich 5
Taipei 5
Bologna 4
Foggia 4
Frankfurt am Main 4
Fuzhou 4
Hefei 4
Mexico 4
Reading 4
Redmond 4
Riposto 4
Wandsworth 4
Caserta 3
Chengdu 3
Chiswick 3
Civitavecchia 3
Copenhagen 3
Council Bluffs 3
Totale 6.406
Nome #
The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium 325
Valutazione dell’insulino-sensibilità tramite clamp euglicemico iperinsulinemico in bambini in terapia sostitutiva con GH. 275
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 219
NANOG plays a hierarchical role in the transcription network regulating the pluripotency and plasticity of adipose tissue-derived stem cells 176
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 173
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency 167
Hepatic steatosis index in acromegaly: Correlation with insulin resistance regardless of the disease control 165
Superior mesenteric artery syndrome: Clinical, endoscopic, and radiological findings 160
Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency 158
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 156
Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency 152
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association? 151
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 149
Development of a fuzzy expert system for the control of glycemia in type 1 diabetic patients 147
Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders 140
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children 136
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency 136
Circulating Irisin Levels in Children with GH Deficiency before and after 1 Year of GH Treatment 135
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis 134
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 132
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 131
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report 126
Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency 126
The treatment of hyperinsulinemic hypoglycaemia in adults: an update 124
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 122
Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. 119
The metabolic outcomes of growth hormone treatment in children are gender specific 119
NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND 118
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis 117
Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide 117
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study 116
Relationship between body fat distribution and blood disorders in patients with visceral obesity with and without diabetes mellitus 116
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy (APECED) in Sicily: confirmation that R203X is the peculiar AIRE gene mutation. 113
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? 113
COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTRE EXPERIENCE. 112
Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature 112
Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease 110
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 107
The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence” 107
Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia 105
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 100
Off-line control of the postprandial glycemia in type 1 diabetes patients by a fuzzy logic decision support 96
Body composition assessment for the definition of cardiometabolic risk. 96
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY 94
Sviluppo di un sistema di supporto decisionale tipo Fuzzy per il controllo della glicemia post-prandiale nel diabete mellito tipo 1 93
Impact of atorvastatin plus n-3 PUFA on metabolic, inflammatory and coagulative parameters in metabolic syndrome without and with type 2 diabetes mellitus 89
Improved cardiovascular and cardiometabolic risk in patients with type 1 diabetes and autoimmune polyglandular syndrome switched from glargine to degludec due to hypoglycaemic variability 87
Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease 86
Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease 84
Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study 84
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 77
Efficacia della associazione Atorvastatina e n-3 PUFA in pazienti affetti da dislipidemia combinata e ad alto rischio di eventi cardiovascolari 75
IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH 74
Traitement séquential avec des corticostéroides dans les ophtalmopathy Graves 73
Effetti a lungo termine del trattamento con Simvastatina ed Ezetimibe sui livelli di HDL-C e hs-PCR in pazienti affetti da Ipercolesterolemia familare(FH) con pregresso IMA e/o Lesione carotidea 72
Glucocorticoid excess and COVID-19 disease 71
More favorable metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 69
Maggiore rischio cardiometabolico in pazienti di razza non caucasica affetti da diabete mellito di tipo 1 idiopatico rispetto alla forma autoimmune in pazienti caucasici. 68
Utilizzo del Visceral Adiposity Index per l’identificazione di donne con sindrome iperandrogenica a rischio cardiometabolico. 66
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 66
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma 66
Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus 62
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia 62
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 61
INSULIN SECRETION AND SENSITIVITY DURING PASIREOTIDE TREATMENT IN PATIENTS WITH RECURRENT CUSHING DISEASE: A CASE SERIES 61
Miglioramento clinico e metabolico in pazienti affetti da diabete mellito tipo 1 associato ad altre endocrinopatie (APS) dopo shift della terapia insulinica basale con glargine a degludec 61
GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy 60
Insulin sensitivity and visceral adiposity index (VAI) in women with functional secondary amenorrhea. 58
IL CONSUMO DI BEVANDE RICCHE DI ACIDO ORTOFOSFORICO COME FATTORE DI RISCHIO PER LO SVILUPPO DI IPOCALCEMIA: IL CASO DI UNA DONNA CON IPOPARATIROIDISMO POST-CHIRURGICO 55
Maggior rischio cardiometabolico nelle donne affette da Cushing, anche in assenza di una franca Sindrome Metabolica. 54
Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease 54
ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. 54
Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study 50
Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus 50
Poor diagnostic value of the euglycemic-hyperinsulinemic clamp in the clinical assessment of insulin resistant women with PCOS. 49
Clinical and metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 47
Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. 41
COVID-19 and the Pancreas: A Narrative Review 40
Valutazione dell’insulino-sensibilità e della funzione adiposa viscerale nel diabete mellito tipo 1 autoimmune ed idiopatico. 40
Modificazioni di insulino-secrezione, insulino-sensibilità e funzione adiposa durante terapia con pasireotide in un gruppo di pazienti con malattia di Cushing 37
LONG-TERM METABOLIC EFFECTS OF GH THERAPY IN CHILDREN WITH IDIOPATHIC GH DEFICIENCY 36
Predictive factors of polycystic ovary syndrome in girls with precocious pubarche 36
CONVENTIONAL GLUCOCORTICOID REPLACEMENT THERAPY VS. DUAL-RELEASE HYDROCORTISONE: EFFECTS ON INFLAMMATION AND IMMUNE PROFILE IN PATIENTS WITH PRIMARY ADRENAL INSUFFICIENCY AND IMPLICATIONS OF THERAPY RESPONSE PREDICTORS 35
Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. 35
Microbiota Gut-Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease. 35
IS THE DEGREE OF URINARY FREE CORTISOL AN EXHAUSTIVE PARAMETER FOR DEFINING CUSHING SYNDROME SEVERITY? 34
GENOMIC AND PROTEOMIC EVALUATION OF VISCERAL AND SUBCUTANEOUS ADIPOSE DERIVED STEM CELLS AND FUNCTIONAL ROLES OF PLURIPOTENCY TRANSCRIPTION FACTORS 33
Miglioramento dell'insulino-sensibilità e dell'insulino-secrezione dopo switch da terapia con glucocorticoidi tradizionali a idrocortisone "dual release" in pazienti affetti da iposurrenalismo 33
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus 32
Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras 32
Emerging therapies in pheochromocytoma and paraganglioma: Immune checkpoint inhibitors in the starting blocks 31
Thyroid function during long-term GH treatment in children affected by idiopathic GH deficiency 30
EFFECT OF SWITCH FROM CONVENTIONAL GLUCOCORTICOIDS TO “DUAL RELEASE HYDROCORTISONE” (DR-HC) ON METABOLIC PROFILE AND QUALITY OF LIFE IN ADULT PATIENTS WITH SECONDARY ADRENAL INSUFFICIENCY (SAI): RESULTS OF THREE MONTHS FOLLOW-UP 30
Revaluation of the clinical and metabolic behavior of GHD children during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA) 30
Maternal-foetal complications in pregnancy: a retrospective comparison between type 1 and type 2 diabetes mellitus. 30
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. 30
Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology. 28
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 28
Tenapanor for the treatment of irritable bowel syndrome with constipation. 26
Ultrasound Parameters Can Accurately Predict the Risk of Malignancy in Patients with "Indeterminate TIR3b" Cytology Nodules: A Prospective Study 25
Totale 9.027
Categoria #
all - tutte 41.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.622 0 0 0 0 265 347 218 164 196 120 243 69
2020/20211.162 76 67 84 88 91 90 93 103 137 98 108 127
2021/20221.166 39 168 41 62 45 59 46 65 199 161 55 226
2022/20231.355 146 261 22 122 139 190 74 111 182 8 66 34
2023/2024711 26 99 29 60 56 166 102 49 10 26 17 71
2024/2025563 67 127 132 199 38 0 0 0 0 0 0 0
Totale 9.396